Skip Nav Destination
Issues
15 August 2009
-
Cover Image
Cover Image
Confocal microscopy analysis of UMUC3 after expression of miR-200c. Cells were costained for ERRFI-1 (red pixels), EGFR (green pixels) and a DNA dye, showing the nucleus (blue pixels). For further details, please see Adam and coworkers on page 5060 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Perspective
Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2
D. Gareth Evans; Michel Kalamarides; Kim Hunter-Schaedle; Jaishri Blakeley; Jeffrey Allen; Dusica Babovic-Vuskanovic; Allan Belzberg; Gideon Bollag; Ruihong Chen; Emmanuelle DiTomaso; John Golfinos; Gordon Harris; Abraham Jacob; Ganjam Kalpana; Matthias Karajannis; Bruce Korf; Razelle Kurzrock; Meng Law; Andrea McClatchey; Roger Packer; Pamela Roehm; Allan Rubenstein; William Slattery, III; James H. Tonsgard; D. Bradley Welling; Brigitte Widemann; Kaleb Yohay; Marco Giovannini
Review
Human Cancer Biology
miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy
Liana Adam; Meng Zhong; Woonyoung Choi; Wei Qi; Milena Nicoloso; Ameeta Arora; George Calin; Hua Wang; Arlene Siefker-Radtke; David McConkey; Menashe Bar-Eli; Colin Dinney
Profiling of Chemonaive Osteosarcoma and Paired-Normal Cells Identifies EBF2 as a Mediator of Osteoprotegerin Inhibition to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis
Ana Patiño-García; Marta Zalacain; Cecilia Folio; Carolina Zandueta; Luis Sierrasesúmaga; Mikel San Julián; Gemma Toledo; Javier De Las Rivas; Fernando Lecanda
Cancer Therapy: Preclinical
Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-κB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell–Mediated Cytotoxicity
Boris Böll; Farag Eltaib; Katrin S. Reiners; Bastian von Tresckow; Samir Tawadros; Venkateswara R. Simhadri; Francis J. Burrows; Karen Lundgren; Hinrich P. Hansen; Andreas Engert; Elke Pogge von Strandmann
Reexpression of Human Somatostatin Receptor Gene 2 Gene Mediated by Oncolytic Adenovirus Increases Antitumor Activity of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand against Pancreatic Cancer
Zhenwei Zhang; Yangbin Huang; Kam Newman; Jinfa Gu; Xuemei Zhang; Hua Wu; Ming Zhao; Zhiqun Xianyu; Xinyuan Liu
Imaging, Diagnosis, Prognosis
Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B
Annette Paschen; Antje Sucker; Bettina Hill; Iris Moll; Marc Zapatka; Xuan Duc Nguyen; Geok Choo Sim; Isabelle Gutmann; Jessica Hassel; Jürgen C. Becker; Alexander Steinle; Dirk Schadendorf; Selma Ugurel
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Scott J. Rodig; Mari Mino-Kenudson; Sanja Dacic; Beow Y. Yeap; Alice Shaw; Justine A. Barletta; Hannah Stubbs; Kenny Law; Neal Lindeman; Eugene Mark; Pasi A. Janne; Thomas Lynch; Bruce E. Johnson; A. John Iafrate; Lucian R. Chirieac
Imaging of αvβ3 Expression by a Bifunctional Chimeric RGD Peptide not Cross-Reacting with αvβ5
Antonella Zannetti; Silvana Del Vecchio; Francesca Iommelli; Annarita Del Gatto; Stefania De Luca; Laura Zaccaro; Angela Papaccioli; Jvana Sommella; Mariarosaria Panico; Antonio Speranza; Paolo Grieco; Ettore Novellino; Michele Saviano; Carlo Pedone; Marco Salvatore
Prognostic Significance of Interleukin-6 Single Nucleotide Polymorphism Genotypes in Neuroblastoma: rs1800795 (Promoter) and rs8192284 (Receptor)
Joanne P. Lagmay; Wendy B. London; Thomas G. Gross; Amanda Termuhlen; Nicholas Sullivan; Amy Axel; Bethany Mundy; Mark Ranalli; Jason Canner; Patrick McGrady; Brett Hall
Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid–Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides
Rosalba Mansi; Xuejuan Wang; Flavio Forrer; Stefan Kneifel; Maria-Luisa Tamma; Beatrice Waser; Renzo Cescato; Jean Claude Reubi; Helmut R. Maecke
Cancer Therapy: Clinical
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros; Angelika M. Burger; Sunita Philip; Ruben Niesvizky; Sarah S. Kolla; Olga Goloubeva; Carolynn Harris; James Zwiebel; John J. Wright; Igor Espinoza-Delgado; Maria R. Baer; Julianne L. Holleran; Merrill J. Egorin; Steven Grant
Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial
Ji-Yeob Choi; William E. Barlow; Kathy S. Albain; Chi-Chen Hong; Javier G. Blanco; Robert B. Livingston; Warren Davis; James M. Rae; I-Tien Yeh; Laura F. Hutchins; Peter M. Ravdin; Silvana Martino; Alan P. Lyss; C. Kent Osborne; Martin D. Abeloff; Daniel F. Hayes; Christine B. Ambrosone
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
David M. Jackman; Vincent A. Miller; Leigh-Anne Cioffredi; Beow Y. Yeap; Pasi A. Jänne; Gregory J. Riely; Marielle Gallegos Ruiz; Giuseppe Giaccone; Lecia V. Sequist; Bruce E. Johnson
Letter to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds